RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $54
RBC Capital analyst Luca Issi maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success rate of 22.6%
Intellia Therapeutics (NTLA) Receives a Buy From RBC Capital
Jones Trading Initiates Coverage On Intellia Therapeutics With Buy Rating, Announces Price Target of $41
Intellia Therapeutics Analyst Ratings
JonesTrading Initiates Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $41
JonesTrading analyst Debanjana Chatterjee initiates coverage on $Intellia Therapeutics(NTLA.US)$ with a buy rating, and sets the target price at $41.According to TipRanks data, the analyst has a
Intellia Therapeutics: A Bullish Outlook on Gene Editing Innovation and Market Potential